Interleukin-7 Human Recombinant ( IL 7 Human )

Catalog # PT_41214

Print

$201.00
DescriptionInterleukin-7 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 153 amino acids and having a molecular mass of 17412 Dalton. The IL-7 is purified by proprietary chromatographic
Product Size: 2ug
Quantity

Data sheet

Formulation
Lyophilized from a concentrated (1mg/ml) solution in water containing 1x PBS pH-7.4.
Solubility
It is recommended to reconstitute the lyophilized Interleukin -7 in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Purity
Greater than 95.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.
Description
Interleukin-7 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 153 amino acids and having a molecular mass of 17412 Dalton. The IL-7 is purified by proprietary chromatographic techniques.
Protein Background
IL-7 is a cytokine important for B and T cell development. This cytokine and the hepatocyte growth factor (HGF) form a heterodimer that functions as a pre-pro-B cell growth-stimulating factor. This cytokine is found to be a cofactor for V(D)J rearrangemen
Expression host
Escherichia Coli.
Synonyms
Lymphopoietin 1 (LP-1), pre-B cell factor, IL-7.
Reagent Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Stability
Lyophilized Interleukin-7 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IL7 should be stored at 4°C between 2-7 days and for future use below -18°C.For long term storage it is recommended to
Amino acid sequence
MDCDIEGKDG KQYESVLMVS IDQLLDSMKE IGSNCLNNEF NFFKRHICDA NKEGMFLFRA ARKLRQFLKM NSTGDFDLHL LKVSEGTTIL LNCTGQVKGR KPAALGEAQP TKSLEENKSL KEQKKLNDLC FLKRLLQEIK TCWNKILMGT KEH.
Biological Activity
The ED50 as determined by the dose-dependant stimulation of murine IXN/2B cells is
References
Title: Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancerPublication: Gene therapy 16.5 (2009): 596-604.Link: http://www.nature.com/gt/journal/v16/n5/full/gt2008189a.html
New